Abstract
Purpose: To develop a simple, sensitive and rapid reverse phase HPLC method for the simultaneous analysis of metoprolol succinate and hydrochlorothiazide in a solid dosage form. Methods: The drugs were analysed by a reverse phase C-18 column using 50mM di-sodium hydrogen phosphate:methanol:acetonitrile in a ratio of 525:225:250 as mobile phase. The flow rate was 1 ml/min and the compounds were detected by a UV-detector at 222 nm at a column temperature of 24 ± 2 ºC. The method was statistically validated for linearity and accuracy. Results: The retention time and drug content of metoprolol succinate and hydrochlorothiazide were 5.38 min, 96.05 % and 3.04 min., 97.64 %, respectively. Conclusion: The study shows that the developed method is simple and accurate and that it would be suitable for the simultaneous determination of metoprolol succinate and hydrochlorothiazide in pharmaceutical formulations.Keywords: Metoprolol succinate; Hydrochlorothiazide; Simultaneous analysis; High performance liquid chromatography; Tablet formulation
Highlights
Metoprolol succinate is a beta-blocker and while hydrochlorothiazide is a potent thiazide diuretic that enhances natriuresis, leading to reduction in plasma volume and cardiac output
Metoprolol succinate is 2-propanol, 1-[4-(2methoxyethyl) phenoxy]-3-[(1-methylethyl) amino], (±), butanedioate and Hydrochlorothiazide is 6-chloro-3,4-dihydro2H- 1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide. Both drugs are official in the British Pharmacopoeia and United States Pharmacopoeia but their combination is not and, to the best of our knowledge, no official method has yet been developed for their separation and assay [5,6]
In order to develop an effective method for the analysis of the drugs in pharmaceutical formulations, preliminary tests were performed in order to select adequate and optimum conditions
Summary
Metoprolol succinate is a beta-blocker and while hydrochlorothiazide is a potent thiazide diuretic that enhances natriuresis, leading to reduction in plasma volume and cardiac output It is used widely alone or in combination with other antihypertensive drugs for the treatment of cardiovascular disorders, viz, hypertension, angina, and congestive cardiac failure [1-4]. Metoprolol succinate is 2-propanol, 1-[4-(2methoxyethyl) phenoxy]-3-[(1-methylethyl) amino]-, (±)-, butanedioate and Hydrochlorothiazide is 6-chloro-3,4-dihydro2H- 1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide. Both drugs are official in the British Pharmacopoeia and United States Pharmacopoeia but their combination is not and, to the best of our knowledge, no official method has yet been developed for their separation and assay [5,6]. Application of an HPLC method with high sensitivity and selectivity will find use for the determination of metoprolol succinate and hydrochlorothiazide in pharmaceutical formulations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
